Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 20;30(161):210010.
doi: 10.1183/16000617.0010-2021. Print 2021 Sep 30.

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

Affiliations
Review

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

James D Chalmers et al. Eur Respir Rev. .

Abstract

Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: J.D. Chalmers reports grants and personal fees from AstraZeneca, Conflict of interest: Boehringer Ingelheim, GlaxoSmithKline and Insmed; grants from Gilead Sciences and Grifols; and personal fees from Chiesi, Novartis and Zambon, outside the submitted work. Conflict of interest: J. van Ingen reports advisory board membership from Insmed, outside the submitted work. Conflict of interest: R. van der Laan is an employee of Insmed. Conflict of interest: J-L. Herrmann has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Nontuberculous mycobacterial (NTM) pulmonary disease pathogenesis from the environment to the lung. Multiple mechanisms of entry into the macrophage: the vicious cycle of infection. Reproduced and modified from [20] with permission.
FIGURE 2
FIGURE 2
Structure of liposomes for drug delivery. a) Conventional liposome. b) Theranostic liposome. c) PEGylated liposome. d) Ligand-targeted liposome. PEG: polyethylene glycol. Reproduced and modified from [83] with permission.

References

    1. Cowman S, van Ingen J, Griffith DE, et al. Non-tuberculous mycobacterial pulmonary disease. Eur Respir J 2019; 54: 1900250. doi: 10.1183/13993003.00250-2019 - DOI - PubMed
    1. Qvist T, Taylor-Robinson D, Waldmann E, et al. Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. J Cyst Fibros 2016; 15: 380–385. doi: 10.1016/j.jcf.2015.09.007 - DOI - PMC - PubMed
    1. Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012; 16: 408–414. doi: 10.5588/ijtld.11.0148 - DOI - PubMed
    1. Gochi M, Takayanagi N, Kanauchi T, et al. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. Respir Med 2015; 5: e008058. doi: 10.1136/bmjopen-2015-008058 - DOI - PMC - PubMed
    1. Park TY, Jeong BH, Chon HR, et al. Lung function decline according to clinical course in nontuberculous mycobacterial lung disease. Chest 2016; 150: 1222–1232. doi: 10.1016/j.chest.2016.06.005 - DOI - PubMed

MeSH terms